ContraFect and China's IVDC Collaborate on Universal Flu Treatment

ContraFect Corporation, a New York biotech, and China's National Institute for Viral Disease Control and Prevention, China CDC (IVDC) formed a collaboration to advance ContraFect's universal treatment for flu. CF-404, currently in pre-clinical development, is comprised of three fully human monoclonal antibodies. In animal models, using a low dose, it provided protection against all human strains of flu, including pandemic strains. The IVDC will conduct tests of CF-404 on China flu strains. Financial details were not disclosed. More details.... Stock Symbol: (NSDQ: CRFX) Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.